NY-ESO-1/LAGE-1 HLA class I/II peptide vaccine

Developed for: prostate cancer
Investigated by: Baylor College of Medicine · National Cancer Institute (NCI)

today NCT00616291 · Ph 1

2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1	NCT00616291	Apr 2006 → Jul 2011	prostate cancer	Baylor College of Medicine	Completed	No outcome recorded

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	NY-ESO-1/LAGE-1 HLA class I/II peptide vaccine	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00616291 ↗
Modality	Peptide	“NY-ESO-1/LAGE-1 peptide vaccine” NCT00616291 ↗
Route	Subcutaneous	“NY-ESO-1/LAGE-1 class-I and class-II vaccine administered subcutaneously” NCT00616291 ↗